Pharmaceuticals
Diagnostics

Nanobiotix reports NBTXR3 NSCLC data and €86m raise

Nanobiotix posted H1 2026 results showing encouraging NBTXR3 response rates in lung and head and neck cancer trials, backed by a freshly raised €86 million.
Nanobiotix posted H1 2026 results showing encouraging NBTXR3 response rates in lung and head and neck cancer trials, backed by a freshly raised €86 million.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Biologics
Pharmaceuticals

CARVYKTI gives five-year remissions to 50% in early-line myeloma

Five-year CARTITUDE-2 data show half of early-line RRMM patients remained alive and progression-free after a single cilta-cel infusion, with no
Five-year CARTITUDE-2 data show half of early-line RRMM patients remained alive and progression-free after a single cilta-cel infusion, with no
The Biotech Times Editorial Team  · 
Proteomics
Diagnostics
Biologics

Alamar Biosciences platform underpins Lancet Neurology lecanemab study

A Washington University cohort study used Alamar's 130-protein plasma panel to show amyloid clearance and cognitive response reflect distinct biological processes.
A Washington University cohort study used Alamar's 130-protein plasma panel to show amyloid clearance and cognitive response reflect distinct biological processes.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Biologics

CARVYKTI: half of earlier-line myeloma patients free at five years

Five-year CARTITUDE-2 data show 50% of RRMM patients remained alive and progression-free after a single cilta-cel infusion, with overall survival at
Five-year CARTITUDE-2 data show 50% of RRMM patients remained alive and progression-free after a single cilta-cel infusion, with overall survival at
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

IMUNON reports 14.7-month OS gain from Phase 2 ovarian cancer trial

IMUNON's IMNN-001 showed a 14.7-month median overall survival advantage over standard care in a 112-patient Phase 2 study, as its
IMUNON's IMNN-001 showed a 14.7-month median overall survival advantage over standard care in a 112-patient Phase 2 study, as its
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

MediciNova completes double-blind phase of COMBAT-ALS ibudilast trial

MediciNova has finished the double-blind portion of its 234-patient Phase 2b/3 ALS trial and expects topline results by end of 2026.
MediciNova has finished the double-blind portion of its 234-patient Phase 2b/3 ALS trial and expects topline results by end of 2026.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Rezolute's ersodetug shows strong interim data in tumour HI trial

Seven of eight enrolled participants met the primary endpoint in the upLIFT Phase 3 study; topline results are expected before end of 2026.
Seven of eight enrolled participants met the primary endpoint in the upLIFT Phase 3 study; topline results are expected before end of 2026.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Satellos wins FDA IND clearance for forazapadin in FSHD

Satellos Bioscience has cleared an IND for its AAK1 inhibitor in a second muscle disease, backed by US$5m from the FSHD Canada Foundation.
Satellos Bioscience has cleared an IND for its AAK1 inhibitor in a second muscle disease, backed by US$5m from the FSHD Canada Foundation.
The Biotech Times Editorial Team  · 
Biologics
Cell & Gene Therapy
Pharmaceuticals

Transgene reports 100% DFS at 41 months for TG4050 HNSCC vaccine

Transgene's personalised neoantigen vaccine TG4050 maintained 100% disease-free survival at over three years in resected head and neck cancer, with Phase 2 topline
Transgene's personalised neoantigen vaccine TG4050 maintained 100% disease-free survival at over three years in resected head and neck cancer, with Phase 2 topline
The Biotech Times Editorial Team  · 
Medical Devices
Digital Health

Precision Neuroscience closes $250m Series D for BCI expansion

The New York BCI company raised an oversubscribed round co-led by Pershing Square, bringing total funding to $430m since its 2021 founding.
The New York BCI company raised an oversubscribed round co-led by Pershing Square, bringing total funding to $430m since its 2021 founding.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Genomics

Prime Medicine wins FDA IND clearance for PM647 in AATD

The Cambridge biotech's in vivo Prime Editor targets the root genetic cause of alpha-1 antitrypsin deficiency, with first-in-human data expected in
The Cambridge biotech's in vivo Prime Editor targets the root genetic cause of alpha-1 antitrypsin deficiency, with first-in-human data expected in
The Biotech Times Editorial Team  · 
Pharmaceuticals

Nuvectis NXP200 wins Breakthrough Therapy Designation in China for HGG

China's CDE has granted Breakthrough Therapy Designation to NXP200, a brain-penetrant BRAF inhibitor, for recurrent BRAF V600-mutant high-grade glioma.
China's CDE has granted Breakthrough Therapy Designation to NXP200, a brain-penetrant BRAF inhibitor, for recurrent BRAF V600-mutant high-grade glioma.
The Biotech Times Editorial Team  · 
Subscribe to